Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America

BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of...

Descripción completa

Detalles Bibliográficos
Autores principales: Forrat, Rémi, Dayan, Gustavo H, DiazGranados, Carlos A, Bonaparte, Matthew, Laot, Thelma, Capeding, Maria Rosario, Sanchez, Leilani, Coronel, Diana Leticia, Reynales, Humberto, Chansinghakul, Danaya, Hadinegoro, Sri Rezeki S, Perroud, Ana Paula, Frago, Carina, Zambrano, Betzana, Machabert, Tifany, Wu, Yukun, Luedtke, Alexander, Price, Brenda, Vigne, Claire, Haney, Owen, Savarino, Stephen J, Bouckenooghe, Alain, Noriega, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442794/
https://www.ncbi.nlm.nih.gov/pubmed/33822015
http://dx.doi.org/10.1093/cid/ciab288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442794/
https://www.ncbi.nlm.nih.gov/pubmed/33822015
http://dx.doi.org/10.1093/cid/ciab288

Ejemplares similares